Hims & Hers Health/$HIMS
1D1W1MYTD1Y5YMAX
Capital at risk
About Hims & Hers Health
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
- Ticker
- $HIMS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 2,442
- Headquarters
- San Francisco, United States
- Website
- www.hims.com
HIMS Metrics
BasicAdvanced
$6.5B
-
-$0.62
2.42
-
Price and volume
Market cap
$6.5B
Beta
2.42
52-week high
$65.30
52-week low
$13.74
Average daily volume
11M
Financial strength
Current ratio
0.934
Quick ratio
0.82
Long term debt to equity
4.736
Total debt to equity
4.771
Interest coverage (TTM)
-10.44%
Profitability
EBITDA (TTM)
-10.177
Gross margin (TTM)
69.53%
Net profit margin (TTM)
-5.51%
Operating margin (TTM)
-3.78%
Effective tax rate (TTM)
13.19%
Revenue per employee (TTM)
$1,060,000
Management effectiveness
Return on assets (TTM)
-2.21%
Return on equity (TTM)
-32.03%
Valuation
Price to revenue (TTM)
2.48
Price to book
20.15
Price to tangible book (TTM)
-5.44
Price to free cash flow (TTM)
103.722
Free cash flow yield (TTM)
0.96%
Free cash flow per share (TTM)
0.27
Growth
Revenue change (TTM)
28.04%
Earnings per share change (TTM)
-178.84%
3-year revenue growth (CAGR)
53.65%
3-year earnings per share growth (CAGR)
39.88%
What the Analysts think about HIMS
Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.
Analyst projections of the future price of Hims & Hers Health stock.
Bulls say / Bears say
Q2 revenue rose 38% year on year to $753.2 million, while subscribers grew 19% and monthly revenue per average subscriber rose 21%. Management also raised 2026 revenue guidance to $3.1 billion–$3.3 billion, suggesting the recovery is broader than a single strong quarter. (Hims & Hers Health, The Motley Fool)
The Eucalyptus acquisition has rapidly increased Hims & Hers’ international reach, with rest-of-world revenue rising more than 17-fold to $131.4 million in Q2. The combined platform now operates across several major markets, giving the company more room to grow beyond the US. (Morningstar, Hims & Hers Health)
The Novo Nordisk partnership gives Hims & Hers access to branded Wegovy and Ozempic while reducing its reliance on legally contested compounded products. Management also reported better marketing efficiency and expects AI-led improvements in support and retention to help offset the lower-margin product mix. (Yahoo Finance, The Motley Fool)
Growth is currently coming with a sharp profitability trade-off: Q2 gross margin fell to 64% from 76% a year earlier, adjusted EBITDA fell to $60.3 million, and the company swung to an $86.3 million net loss. Management expects branded weight-loss products and international revenue to keep gross margins below historical levels. (Hims & Hers Health, The Motley Fool)
Regulatory scrutiny remains a material risk to the weight-loss business. The FDA has warned telehealth firms and compounders about unapproved GLP-1 products, citing adverse-event reports, dosing errors and supply-chain concerns, which could restrict a product area that has been important to Hims & Hers’ growth. (Proactive Investors, Yahoo Finance)
The next phase depends on executing a difficult shift from high-margin compounding to branded distribution and integrating international acquisitions. JPMorgan says investors still need proof that branded GLP-1 adoption, newer specialties, international expansion and durable margin improvement can all work together. (Yahoo Finance, Morningstar)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
HIMS Financial Performance
Revenues and expenses
HIMS Earnings Performance
Company profitability
Upcoming events
No upcoming events
HIMS News
AllArticlesVideos
HIMS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Hims Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Newsfile Corp2 days ago
Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Action
Business Wire2 days ago
Kaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors to Seek a Leadership Role Before Deadline on November 2, 2026
Newsfile Corp2 days ago
Funds containing HIMS
AllEURUSDGBP
Fund name | Fund size | $HIMS weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.46% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.20% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.17% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.17% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.